XGN · Exagen Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| $72M – $75M | $71.12M | $66.58MG | $55.64M | $52.55M | $45.56M | $48.3M | $41.98M | $40.39M | |
| — | $29.42M | $27.78M | $22.53M | $23.09M | $24.21M | $20.59M | $16.56M | $18.81M | |
| — | $41.7M | $38.8M | $33.11M | — | — | — | — | — | |
| — | — | 58.28% | 59.51% | — | — | — | — | — | |
| — | $6.47M | $6.25M | $5.38M | $4.87M | $9.88M | $7.24M | $3.57M | $2.18M | |
| — | $48.45M | $46.62M | $41.37M | $47.43M | $52.02M | $44.54M | $37.03M | $28.7M | |
| — | — | — | — | — | — | — | — | $0 | |
| — | $2.4M | $2.1M | $1.7M | $2.2M | $1.6M | $900K | $500K | $600K | |
| — | $54.91M | $52.87M | $46.75M | $75.39M | $91.61M | $72.37M | $57.16M | $49.69M | |
| — | -$13.21M | -$14.07M | -$13.64M | -$22.84M | -$46.05M | -$24.07M | -$15.19M | -$9.3M | |
| — | — | -21.13% | -24.51% | -43.46% | -101.07% | -49.83% | -36.18% | -23.02% | |
| — | -$10.81M | -$11.97M | -$11.94M | -$20.64M | -$44.45M | -$23.17M | -$14.69M | -$8.7M | |
| — | $5.12M | $4.32M | $2.23M | $2.34M | $2.45M | $2.63M | $2.57M | $3.49M | |
| — | — | $289K | $767K | — | — | — | — | — | |
| — | — | — | — | — | — | $16K | $984K | $510K | |
| — | $50K | $51K | $12K | $33K | -$282K | $175K | -$79K | $25K | |
| — | -$18.92M | -$19.95M | -$15.12M | -$23.69M | -$47.39M | -$26.85M | -$16.69M | -$12.04M | |
| — | — | -29.97% | -27.17% | -45.08% | -104% | -55.59% | -39.75% | -29.81% | |
| USD/shares | — | — | -$0.93 | -$0.83 | -$1.34 | -$2.77 | -$1.68 | — | — |
| USD/shares | — | — | -$0.93 | -$0.83 | -$1.34 | -$2.77 | -$1.68 | — | — |
| shares | — | — | 21.56M | 18.2M | 17.68M | 17.08M | 15.97M | 12.63M | 3.58M |
| shares | — | — | 21.56M | 18.2M | 17.68M | 17.08M | 15.97M | 12.63M | 3.58M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 13 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Reportable Segment | $66,575,000 | $55,641,000 | $52,548,000 | — | — |
| Client | — | — | — | $4,392,000 | $608,000 |
| Healthcare Insurers | — | — | — | $23,984,000 | $21,070,000 |
| Janssen SIMPONI | — | — | — | $1,476,000 | $0 |
| All Other Segments | — | — | — | $639,000 | $738,000 |
| Government | — | — | — | $9,896,000 | $10,024,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$14,070,000 | -$13,636,000 | -$22,837,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -21.1% | -24.5% | -43.5% |